Source comparison
Cerebrolysin, P21, and Dihexa: Mechanism Comparison
Cerebrolysin Blood-brain barrier stabilisation, anti-inflammatory, neurotrophic support Persistent headache, photophobia, vascular symptoms IV infusion (30–50mL daily × 10–21 days) High. Multiple RCTs in moderate-severe TBI Strongest evidence base for acute ne
This comparison does not assign a generated winner or score.
- Cerebrolysin
- Blood-brain barrier stabilisation, anti-inflammatory, neurotrophic support
- Persistent headache, photophobia, vascular symptoms
- IV infusion (30–50mL daily × 10–21 days)
- High. Multiple RCTs in moderate-severe TBI
- Strongest evidence base for acute neuroprotection; requires IV access
- P21
- CREB-mediated synaptic plasticity, dendritic spine growth
- Memory deficits, learning impairment, cognitive fog
- Subcutaneous (1–2mg daily × 14–28 days)
- Moderate. Preclinical models only, no human TBI trials
- Best mechanistic fit for cognitive recovery; dosing remains empirical
- Dihexa
- HGF/c-Met pathway activation, synaptogenesis
- Cognitive slowing, executive dysfunction
- Oral (5–10mg daily × 21–42 days)
- Low-Moderate. Phase I safety data, no TBI-specific trials
- Most convenient administration; limited human TBI data